New Delhi: Vaccination campaign is being conducted across the country to fight the corona virus. Recently, emergency use of single dose vaccine of Johnson & Johnson was approved. Now the next step is to speed up its domestic production. Along with reserving 300 crore doses of the under-trial Corbevax of Biologicals E, the central government should consider pre-orders to speed up local production. Biological E is also the Indian partner of Johnson & Johnson.
DRL had to struggle in importing the vaccine
Media reports indicate that these vaccines may arrive by October. However, like Johnson & Johnson and Moderna, the Kovovax vaccine and Corbevax are not part of vaccination programs in the US, UK or EU.
The Government of India’s bulk order of 66 crore doses of Covishield and Covaccine in mid-July has taken into account such situations. The fire at Serum Institute’s Pune campus and the struggle for continued production of indigenous covaccine warns that a lot can still go wrong.
There is a need to increase vaccine production
More than 28 crore partially vaccinated people in the country will also need a second shot. In such a situation, due to lack of significant increase in production, the process of dosing to a large population can be slowed down. One good thing is that the average of daily vaccinations last week was 50 lakhs, which was 40 lakhs in the previous week. In such a situation, there is a need to place bulk pre-orders of new vaccines soon.